



Atty. Docket No. P65315US0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

APR 29 2002

TECH CENTER 1600, 2900

In re the Application of:

STÄNDKER et al.

Serial No.: 09 509,559

Group Art Unit: 1647

Filed: November 27, 2000

Examiner: Regina M. DeBerry

For: CADHERIN DERIVED GROWTH FACTOR AND ITS USE

TRANSMITTAL

Commissioner of Patents
Washington, D.C. 20231

Sir:

Transmitted herewith are Amendment and copy of Notice to Comply with Sequence Rules in the above-captioned application.

XX Small Entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.


___ A check in the amount of \$_____ is attached for:

XX If a Petition for Extension of Time is necessary and the Petition and/or the check is not enclosed, this will act as the Petition and applicant herewith petitions the Commissioner to extend the time for response and charge any fees necessary under 37 CFR 1.17 (a)-(d) to Deposit Account No. 06-1358. The Commissioner is also authorized to charge payment of any other additional fees associated with this communication or credit any overpayment to Deposit Account No. 06-1358.

JACOBSON HOLMAN PLLC
400 Seventh Street, N. W.
Washington, D.C. 20004-2201
Atty. Dkt. No.: P65315US0
Date: April 26, 2002
WEP:rdt

R:\HOMF\rdt\mas 2-02 April P65315US0.wpd

By:


William E. Player
Registration No. 31,409

Notice to Comply

APR 26 2002

Application No.

09/509,559

Examiner

Regina M. DeBerry

Applicant(s)

FORSSMANN ET AL.

Art Unit

1647

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990) and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: The instant application fails to fully comply with the sequence rules 37 CFR 1.821-1.825 because each disclosure of a sequence embraced by the definitions set forth in the rules fails to refer to the required sequence identifier (SEQ ID NO:). This occurs in claim 4 and in the specification pages 2, 3, 7, 13, 14, 16 and 17. Appropriate correction is required.

Applicant Must Provide:

- ☐ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing" as well as an amendment directing its entry into the specification.
- ☐ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance 703-287-0200

To Purchase PatentIn Software 703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

RECEIVED
APR 29 2002
TECH CENTER 1600 2901